Mirae Asset Global Investments Co., Ltd. Cassava Sciences Inc Transaction History

Mirae Asset Global Investments Co., Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$18.44 - $26.41 $26,147 - $37,449	-1,418 Reduced 7.92%	16,475 $334,000
Q4 2023 Jan 24, 2024	BUY	$12.64 - $30.11 $17,923 - $42,695	1,418 Added 8.61%	17,893 $402,000
Q3 2022 Nov 10, 2022	BUY	$16.33 - $51.06 $80,506 - $251,725	4,930 Added 42.7%	16,475 $689,000
Q2 2022 Jul 26, 2022	BUY	$17.22 - $38.47 $198,804 - $444,136	11,545 New	11,545 $325,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.